Cutler Group’s Aimmune Therapeutics AIMT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-2,900
| Closed | -$7K | – | 4965 |
|
|
2019
Q4 | $7K | Buy |
+2,900
| New | +$81.1K | ﹤0.01% | 2894 |
|
|
2019
Q2 | – | Sell |
-9,000
| Closed | -$35K | – | 5049 |
|
|
2019
Q1 | $35K | Buy |
9,000
+5,000
| +125% | +$118K | ﹤0.01% | 1671 |
|
|
2018
Q4 | $28K | Sell |
4,000
-8,100
| -67% | -$210K | ﹤0.01% | 1886 |
|
|
2018
Q3 | $53K | Buy |
+12,100
| New | +$342K | ﹤0.01% | 1578 |
|
|
2018
Q2 | – | Sell |
-18,400
| Closed | -$68K | – | 5200 |
|
|
2018
Q1 | $68K | Buy |
18,400
+13,600
| +283% | +$479K | 0.01% | 1455 |
|
|
2017
Q4 | $18K | Sell |
4,800
-4,500
| -48% | -$145K | ﹤0.01% | 2676 |
|
|
2017
Q3 | $4K | Buy |
+9,300
| New | +$200K | ﹤0.01% | 4685 |
|
|
2016
Q4 | – | Sell |
-4,000
| Closed | -$10K | – | 7665 |
|
|
2016
Q3 | $10K | Buy |
+4,000
| New | +$54K | ﹤0.01% | 4264 |
|
Cutler Group's AIMT Position: Q4 2020 in Review
Cutler Group sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 300 shares — an estimated $10K sold.
Cutler Group first reported a position in AIMT in Q3 2016 and held it in 14 quarters. The position peaked at $193K in Q3 2018. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.
- Cutler Group reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
- Cutler Group sold 300 Aimmune Therapeutics shares in Q4 2020, an estimated $10K.
- Cutler Group first reported a position in Aimmune Therapeutics in Q3 2016 and held it in 14 quarters.
- Cutler Group's Aimmune Therapeutics position peaked at $193K in Q3 2018.
- 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.
Based on Cutler Group's 13F filing for Q4 2020, filed 21 Jan 2021.